New neurology studies a ‘wakeup call’ for global health

Related Articles:

• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• Am I being unreasonable? November 16, 2018 Friday 16 November 2018If you’re feeling a bit down and need a quick pick-me-up, you could do worse than browse the discussion threads on mumsnet for a while.I’m not talking about the posts on pregnancy or breast feeding or dealing with toddlers. I’m talking about the “other” section. The most popular category on mumsnet is AIBU, for Am I Being…
• Monthly Research Review – November 2020 November 30, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
• ReWriting the World February 16, 2020 The following is an expanded version of a piece that recently appeared in Times Higher Education. It was written with Prof. Hilal A. Lashuel, the director of the laboratory of molecular and chemical biology of neurodegeneration at the Swiss Federal Institute of Technology Lausanne (École Polytechnique Federale de Lausanne, EPFL).     “That’s it, that’s the cure.” I stood squinting at…
• ReWriting the World February 16, 2020 The following is an expanded version of a piece that recently appeared in Times Higher Education. It was written with Prof. Hilal A. Lashuel, the director of the laboratory of molecular and chemical biology of neurodegeneration at the Swiss Federal Institute of Technology Lausanne (École Polytechnique Federale de Lausanne, EPFL).     “That’s it, that’s the cure.” I stood squinting at…
• ReWriting the World February 16, 2020 The following is an expanded version of a piece that recently appeared in Times Higher Education. It was written with Prof. Hilal A. Lashuel, the director of the laboratory of molecular and chemical biology of neurodegeneration at the Swiss Federal Institute of Technology Lausanne (École Polytechnique Federale de Lausanne, EPFL).     “That’s it, that’s the cure.” I stood squinting at…
• ReWriting the World February 16, 2020 The following is an expanded version of a piece that recently appeared in Times Higher Education. It was written with Prof. Hilal A. Lashuel, the director of the laboratory of molecular and chemical biology of neurodegeneration at the Swiss Federal Institute of Technology Lausanne (École Polytechnique Federale de Lausanne, EPFL).     “That’s it, that’s the cure.” I stood squinting at…
• ReWriting the World February 16, 2020 The following is an expanded version of a piece that recently appeared in Times Higher Education. It was written with Prof. Hilal A. Lashuel, the director of the laboratory of molecular and chemical biology of neurodegeneration at the Swiss Federal Institute of Technology Lausanne (École Polytechnique Federale de Lausanne, EPFL).     “That’s it, that’s the cure.” I stood squinting at…
• ReWriting the World February 16, 2020 The following is an expanded version of a piece that recently appeared in Times Higher Education. It was written with Prof. Hilal A. Lashuel, the director of the laboratory of molecular and chemical biology of neurodegeneration at the Swiss Federal Institute of Technology Lausanne (École Polytechnique Federale de Lausanne, EPFL).     “That’s it, that’s the cure.” I stood squinting at…
• ReWriting the World February 16, 2020 The following is an expanded version of a piece that recently appeared in Times Higher Education. It was written with Prof. Hilal A. Lashuel, the director of the laboratory of molecular and chemical biology of neurodegeneration at the Swiss Federal Institute of Technology Lausanne (École Polytechnique Federale de Lausanne, EPFL).     “That’s it, that’s the cure.” I stood squinting at…
• ReWriting the World February 16, 2020 The following is an expanded version of a piece that recently appeared in Times Higher Education. It was written with Prof. Hilal A. Lashuel, the director of the laboratory of molecular and chemical biology of neurodegeneration at the Swiss Federal Institute of Technology Lausanne (École Polytechnique Federale de Lausanne, EPFL).     “That’s it, that’s the cure.” I stood squinting at…
• ReWriting the World February 16, 2020 The following is an expanded version of a piece that recently appeared in Times Higher Education. It was written with Prof. Hilal A. Lashuel, the director of the laboratory of molecular and chemical biology of neurodegeneration at the Swiss Federal Institute of Technology Lausanne (École Polytechnique Federale de Lausanne, EPFL).     “That’s it, that’s the cure.” I stood squinting at…
• 2020: Year in Review January 1, 2021 # # # # In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2020. Month-by-month we will briefly discuss some of the major pieces of research/ announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies…
• Monthly Research Review – September 2019 September 30, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during September 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Monthy research review – December 2019 December 30, 2019   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during December 2019. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Monthly research review: February 2020 February 29, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during February 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Other news Review…
• Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. March 19, 2019 Related ArticlesGlobal, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019 Mar 14;: Authors: GBD 2016 Neurology Collaborators Abstract BACKGROUND: Neurological disorders are increasingly recognised as major causes of death and disability worldwide. The aim of this analysis from the Global Burden of Diseases, Injuries, and Risk…
• 2019: Year in review December 31, 2019   In this end-of-year post, we review the Parkinson’s research that caught our attention at SoPD HQ in 2019. Month-by-month we will briefly discuss some of the major pieces of research/announcements that have defined the year and advanced our understanding of Parkinson’s. The list is based on nothing more than the author’s personal opinion – apologies to any researchers who…
• Neuroimmunology Experts Survey January 9, 2021 “What attracted me to immunology was that the whole thing seemed to revolve around a very simple experiment: take two different antibody molecules and compare their primary sequences. The secret of antibody diversity would emerge from that. Fortunately at the time I was sufficiently ignorant of the subject not to realize how naive I was being.”— César Milstein From Nobel Lecture…
• AAN 2019 Plenary Session Highlights Research With Implications for Patient Care From Multiple Society Meetings May 9, 2019 The following article is part of conference coverage from the 2019 American Academy of Neurology Annual Meeting (AAN 2019) in Philadelphia, PA. Neurology Advisor’s staff will be reporting breaking news associated with research conducted by leading experts in neurology. Check back for the latest news from AAN 2019. PHILADELPHIA – A plenary session at the 2019 American Academy of Neurology…
• The 2019 Linked Clinical Trials meeting October 16, 2019   Things were a bit quiet on the SoPD over the summer, but for good reasons. There was a short hiatus for a family break, but the rest of the time I was rather occupied with the day job. Tremendous efforts were being made at the Cure Parkinson’s Trust, as we were gearing up for our main event of the…
• Shining a light on Parkinson’s November 7, 2019   NOTE: The information in today’s post should not be considered an endorsement of PhotoPharmics or the treatment they are proposing. The author of this blog has had no communication with the company. The information in this post is provided because the author has been asked by readers to discuss it. In October 2018, at the annual International Movement Disorders…